
News|Articles|October 5, 2026
How Distribution Is Evolving for Today's Targeted Therapies
Author(s)Christopher Van Norman, Stephen Appezzato
McKesson's Chris Van Norman previews his LogiPharma USA keynote on demand signal sharing, AI, and precision distribution for targeted therapies.
Advertisement
Advertisement
As therapies become more targeted and time-sensitive, distribution is demanding more specialized handling, tighter temperature control, and closer coordination between manufacturers and distributors. Christopher Van Norman, senior vice president of supply chain operations at McKesson, addresses those demands at LogiPharma USA 2026, as a speaker in the keynote fireside chat "Racing to Meet the Moment: Supply Chains Built for Today's Therapies."
Related to this article

At LogiPharma USA 2026, Mark Talens explains how end-to-end visibility lets pharma see its value chain across functions, and where supply chain monitoring is headed next.

Octapharma USA's Kerem Tokel, a LogiPharma USA 2026 freight security panelist, discusses theft hotspots, the export of stolen pharmaceutical loads and how to tighten chain of custody.

McKesson's Gene Cavacini on how pharmaceutical distributors manage drug shortages, DSCSA requirements and cold-chain capacity to keep medicines moving.

APIIC's Brian Doty on how repurposing shuttered U.S. plants with advanced manufacturing could make domestic generic drug production viable.

Fragmented data is eroding trust in pharma insights, and AI raises the stakes. A four-step approach can help organizations pay down their “data debt.”

CVS Health’s proposed separation of its retail pharmacy business from insurance and pharmacy benefit management raises a fundamental question: Will changing ownership improve pharmaceutical distribution, competition and patient access, or simply redistribute market power?

APIIC's Brian Doty says renovating shuttered US plants with advanced manufacturing is faster and cheaper than building new to reshore generics.
Advertisement
Advertisement
